Adverse events at least possibly causally-related to palivizumab, both clinical and laboratory, are displayed by system organ class and frequency (common ≥ 1/ 100 to < 1/ 10; uncommon ≥ 1/ 1,000 to < 1/ 100) in studies conducted in premature and bronchopulmonary dysplasia paediatric patients, and congenital heart disease patients (Tables 1 and 2, respectively).